- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Humira to gain fifth indication?
Abbott Laboratories has received a positive opinion recommending approval of Humira (adalimumab) for the treatment of moderate to severe plaque psoriasis.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has granted Abbott Laboratories a positive opinion recommending approval of Humira (adalimumab) for the treatment of moderate to severe plaque psoriasis. If fully approved, psoriasis will be the fifth disease indication for Humira, after rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease.
Abbott is also hoping for FDA approval for this indication.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
